<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814827</url>
  </required_header>
  <id_info>
    <org_study_id>999909060</org_study_id>
    <secondary_id>09-I-N060</secondary_id>
    <nct_id>NCT00814827</nct_id>
  </id_info>
  <brief_title>Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma</brief_title>
  <official_title>Mycobacterial and Opportunistic Infections in HIV-Negative Patients Associated With Autoantibodies to Interferon-gamma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Opportunistic infections are caused by bacteria, mycobacteria, fungi or viruses that do not
      normally cause infections in people with healthy immune systems. Some of these infections can
      cause public health concerns, especially in areas with limited access to treatment. People
      who acquire opportunistic infections usually have diseases that affect their immune systems,
      such as human immunodeficiency virus (HIV), or do not have enough white blood cells to fight
      the infection. However, some people acquire opportunistic infections even though they have
      normal amounts of white blood cells and are free from known diseases that harm their immune
      systems. This study will investigate some of the reasons that otherwise healthy people get
      opportunistic infections to learn more about why some people are more likely to have them.

      This study will include up to 210 HIV-negative males and females older than 18 years of age
      who have opportunistic infections. The patients will be drawn from multiple sites in Thailand
      and Taiwan including Khon Kaen University Hospital, Siriraj Hospital, Ramathibodi Hospital,
      National Taiwan University Hospital, National Cheng-Kung University Hospital

      Patients will undergo an initial evaluation that will include a physical examination, medical
      history, and blood and urine testing. Additional tests will be conducted if the researchers
      consider that the tests are medically necessary to treat the opportunistic infection; the
      results of the tests will be reviewed and saved for study purposes. Depending on the severity
      of the infection, the initial evaluation may take more than 1 day to complete.

      After the evaluation, patients will be given standard and appropriate medicines to treat the
      infections.

      Patients will return for follow-up visits to allow researchers to monitor their condition and
      to assess how well the patient is responding to the treatment. Patients will be evaluated by
      the study researchers at least once a year for 2 years following the initial treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The acquisition of opportunistic infections has been causally linked to innate and acquired
      immunodeficiencies. We have recently identified a population of Asian women with
      autoantibodies to interferon gamma (IFN?), all of whom were diagnosed by virtue of
      nontuberculous mycobacterial infections. Similar patient populations have been reported from
      Thailand, and we have found similar autoantibodies in anonymous serum samples from there. In
      addition, many of the Thai patients who have disseminated or lymphatic nontuberculous
      infections have had other opportunistic infections (OI), such as salmonella, penicilliosis,
      and histoplasmosis. However, they have normal lymphocyte counts and are human
      immunodeficiency virus (HIV) negative. Therefore, the identification of autoantibodies to a
      critical cytokine, the occurrence of opportunistic infections, and the lack of other common
      explanations suggests that this is an important population to study. We propose to enroll
      patients in a natural history study of non-HIV opportunistic infections to explore the
      presence of autoantibodies to cytokines, and to examine potential immunogenetic factors
      influencing the development of this disease. Plasma, cells, and DNA samples will be obtained
      and stored for use in this study. This study will accrue up to 265 patients over 5 years as
      per with follow up for 15 years on each patient, sample size justification and the groups
      described in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 23, 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">224</enrollment>
  <condition>Immunodeficiency</condition>
  <condition>Mycobacterial Infection</condition>
  <condition>Opportunistic Infection</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients must meet all of the following criteria at the time of evaluation to be eligible
        for enrollment into the study cohorts:

        Group 1 (NTM alone):

          1. Past or current infection with NTM proven by culture or specific DNA detection in the
             presence of a compatible clinical picture as judged by the responsible clinician and
             PI on site.

          2. NTM is not felt to iatrogenic (such as indwelling catheter associated or
             post-operative wound infection)

          3. HIV negative within 3 months either prior to the diagnosis of OI, or prior to
             enrollment in this study, if HIV status was unknown at the time of OI

          4. No evidence of active malignancy

          5. No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4
             weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to
             diagnosis of the NTM)

          6. No preexisting immune deficiency

        Group 2 (non-NTM OI with or without NTM):

          1. Patients must have or have had proven infection with one or more of the following
             organisms: disseminated Salmonella, Listeria, Penicillium, Burkholderia pseudomallei,
             Cryptococcus, Histoplasma, Herpes zoster involving 2 or more non-contiguous
             dermatomes, or extradermal involvement or other opportunistic infections not listed
             above, but relevant, as determined by the PI.

          2. Patient may have infection with NTM in addition to one or more of the above
             infection(s).

          3. HIV-negative within 3 months either prior to the diagnosis of OI, or prior to
             enrollment in this study, if HIV status was unknown at the time of OI diagnosis

          4. No evidence of active malignancy

          5. No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4
             weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to
             diagnosis of the NTM)

          6. No preexisting immune deficiency

        Group 3 (diseased control with pulmonary MTB):

          1. Active pulmonary MTB, i.e. patients who have sputum that is either culture positive
             for MTB or AFB positive and responding to therapy for MTB.

          2. Diagnosed with the past 6 months.

          3. No concurrent infections due to NTM or OI listed under above inclusion criteria for
             study subjects

          4. No clinical evidence of HIV

        Group 4 (diseased control with disseminated MTB):

        Disseminated MTB includes infections involving greater than or equal to 2 noncontiguous
        sites, one of which may include pulmonary disease or greater than or equal to 2 separate
        groups of lymph nodes.

          1. Active disseminated MTB or cured disseminated MTB

          2. No concurrent infections due to NTM or OI listed under above inclusion criteria for
             study subjects

          3. HIV negative within 3 months either prior to the diagnosis of MTB, or prior to
             enrollment in this study, if HIV status was unknown at the time of MTB diagnosis

          4. No evidence of active malignancy

          5. No systemic corticosteroids at time of diagnosis of OI (defined as &gt; 4 weeks at a dose
             &gt; 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)

          6. No preexisting immune deficiency.

        Group 5 (Blood Specimen Donors):

        Eligibility criteria not applicable. Blood will be collected from volunteers, and no
        medical evaluation will be performed.

        To be a blood donor the person cannot be excluded per the exclusionary criteria:

          1. Patient &lt; 18 or &gt; 85

          2. Weight &gt; 45 kg (99 lbs)

          3. Receiving chemotherapy of have cancer

          4. Receiving immunosuppressant medications

          5. Have a history of heart, lung, kidney disease of bleeding disorder.

        EXCLUSION CRITERIA:

        Patients will be excluded for the following reasons:

          1. HIV-positive serostatus for groups 1, 2 and 4 (groups 3 and 5 will not be routinely
             performing HIV testing)

          2. Active malignancy

          3. Medical conditions requiring immune modulating therapy (i.e. corticosteroids,
             biological agents, anti-metabolites) and /or chemotherapy

          4. Any other medical conditions unsuitable for this study as determined by the principal
             investigator

          5. Age less than 18 years

          6. Receiving any other investigational study agents when enrolling on this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christa S Zerbe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000 Dec;11(4):321-33. Review.</citation>
    <PMID>10959079</PMID>
  </reference>
  <reference>
    <citation>Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, Martyak LA, Kubak B, Holland SM. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005 Oct 1;175(7):4769-76.</citation>
    <PMID>16177125</PMID>
  </reference>
  <reference>
    <citation>Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, Nicol M, Sch√∂lvinck E, Relman D, Waddell S, Langford P, Sheehan B, Semple L, Wilkinson KA, Wilkinson RJ, Ress S, Hibberd M, Levin M. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005 Sep;115(9):2480-8. Epub 2005 Aug 25.</citation>
    <PMID>16127458</PMID>
  </reference>
  <verification_date>April 26, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interferon-Gamma</keyword>
  <keyword>Autoantibodies</keyword>
  <keyword>Mycobacteria</keyword>
  <keyword>Opportunistic Infections</keyword>
  <keyword>Immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Opportunistic Infections</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

